| A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader HT Huang, D Dobrovolsky, J Paulk, G Yang, EL Weisberg, ZM Doctor, ... Cell chemical biology 25 (1), 88-99. e6, 2018 | 362 | 2018 |
| The IkappaB kinase family phosphorylates the Parkinson’s disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling N Dzamko, F Inesta-Vaquera, J Zhang, C Xie, H Cai, S Arthur, L Tan, ... PloS one 7 (6), e39132, 2012 | 227 | 2012 |
| Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors L Tan, J Wang, J Tanizaki, Z Huang, AR Aref, M Rusan, SJ Zhu, Y Zhang, ... Proceedings of the National Academy of Sciences 111 (45), E4869-E4877, 2014 | 188 | 2014 |
| Chemically induced degradation of anaplastic lymphoma kinase (ALK) CE Powell, Y Gao, L Tan, KA Donovan, RP Nowak, A Loehr, M Bahcall, ... Journal of medicinal chemistry 61 (9), 4249-4255, 2018 | 179 | 2018 |
| Mapping the degradable kinome provides a resource for expedited degrader development KA Donovan, FM Ferguson, JW Bushman, NA Eleuteri, D Bhunia, SS Ryu, ... Cell 183 (6), 1714-1731. e10, 2020 | 169 | 2020 |
| Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor HG Kim, L Tan, EL Weisberg, F Liu, P Canning, HG Choi, SA Ezell, H Wu, ... ACS chemical biology 8 (10), 2145-2150, 2013 | 153 | 2013 |
| Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells S Kozono, YM Lin, HS Seo, B Pinch, X Lian, C Qiu, MK Herbert, CH Chen, ... Nature communications 9 (1), 3069, 2018 | 132 | 2018 |
| Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC KR Amato, S Wang, AK Hastings, VM Youngblood, PR Santapuram, ... The Journal of clinical investigation 124 (5), 2037-2049, 2014 | 122 | 2014 |
| EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer KR Amato, S Wang, L Tan, AK Hastings, W Song, CM Lovly, CB Meador, ... Cancer research 76 (2), 305-318, 2016 | 118 | 2016 |
| Development of selective covalent Janus kinase 3 inhibitors L Tan, K Akahane, R McNally, KMSE Reyskens, SB Ficarro, S Liu, ... Journal of medicinal chemistry 58 (16), 6589-6606, 2015 | 108 | 2015 |
| Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors P Canning, L Tan, K Chu, SW Lee, NS Gray, AN Bullock Journal of molecular biology 426 (13), 2457-2470, 2014 | 107 | 2014 |
| HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib G Yang, SJ Buhrlage, L Tan, X Liu, J Chen, L Xu, N Tsakmaklis, JG Chen, ... Blood, The Journal of the American Society of Hematology 127 (25), 3237-3252, 2016 | 105 | 2016 |
| Suppression of adaptive responses to targeted cancer therapy by transcriptional repression M Rusan, K Li, Y Li, CL Christensen, BJ Abraham, N Kwiatkowski, ... Cancer discovery 8 (1), 59-73, 2018 | 103 | 2018 |
| Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells J Wang, O Mikse, RG Liao, Y Li, L Tan, PA Janne, NS Gray, KK Wong, ... Oncogene 34 (17), 2167-2177, 2015 | 84 | 2015 |
| Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2) L Tan, T Nomanbhoy, D Gurbani, M Patricelli, J Hunter, J Geng, ... Journal of medicinal chemistry 58 (1), 183-196, 2015 | 81 | 2015 |
| Covalent targeting of fibroblast growth factor receptor inhibits metastatic breast cancer WS Brown, L Tan, A Smith, NS Gray, MK Wendt Molecular cancer therapeutics 15 (9), 2096-2106, 2016 | 74 | 2016 |
| Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2 H Shan, J Liu, J Shen, J Dai, G Xu, K Lu, C Han, Y Wang, X Xu, Y Tong, ... Cell chemical biology 28 (6), 855-865. e9, 2021 | 73 | 2021 |
| Hsp40 proteins phase separate to chaperone the assembly and maintenance of membraneless organelles J Gu, Z Liu, S Zhang, Y Li, W Xia, C Wang, H Xiang, Z Liu, L Tan, Y Fang, ... Proceedings of the National Academy of Sciences 117 (49), 31123-31133, 2020 | 71 | 2020 |
| Modulating TRADD to restore cellular homeostasis and inhibit apoptosis D Xu, H Zhao, M Jin, H Zhu, B Shan, J Geng, SA Dziedzic, P Amin, ... Nature 587 (7832), 133-138, 2020 | 63 | 2020 |
| Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss EM Beauchamp, BA Woods, AM Dulak, L Tan, C Xu, NS Gray, AJ Bass, ... Molecular cancer therapeutics 13 (2), 475-482, 2014 | 61 | 2014 |
